Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 28, 2025

Missed Published before the outcome was known, scored automatically when the window closed on October 26, 2025.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$66.49 – $68.45Entry zone — fair-value band

$70.90Published — price the day we called it

$80.63Target — the price the thesis aimed for

$70.49Peak — highest point inside the window, not a realized return

$52.96Window close — end-of-window price, context only

What happened

Missed

Never rose above the publication price inside the window.

Peak price

$70.49

peak on July 28, 2025 — not a realized return

Peak gain

-0.6%

peak, from the publication price

Window close

$52.96

end-of-window price, context only

Days to target

—

Window

July 28, 2025 – October 26, 2025

The thesis — published July 28, 2025

Predicted growth

+15%

over the measurement window

Target price

$80.63

the price the thesis aimed for

Entry zone

$66.49 – $68.45

the fair-value band we waited for

Price at publication

$70.90

published July 28, 2025

Confidence

80%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

After the FDA stopped pharmacies from making copycat versions on July 28, prescriptions for Wegovy jumped 33%, showing Novo can keep its prices strong. The company keeps over 80% of every sales dollar after production costs and holds plenty of cash, so it can build more capacity. The share price has been climbing smoothly, and small pullbacks have been good times to buy since March. Heart-health study results due by October could expand who can use the drug and may lift the stock another 15% in the next three months.

Primary drivers

Wegovy prescriptions up 33% after FDA ban, proving demand is rising fast.
Fast growth and fat profits give clear line of sight to rising earnings and cash.
Upward price trend intact; recent average price climbing, with no excess buying signs.
Heart-health results due by Oct could let doctors offer the drug to more patients.

How it played out

NVO: the thesis did not play out

Lyra published NVO on July 28, 2025 at 70.9, with 15% expected growth and a target of 80.63. The thesis pointed to Wegovy prescriptions up 33%, gross margin above 80%, a steady upward price trend, and heart-health results due by October that could broaden use.

Inside the window, the stock peaked at 70.49 on July 28, with a peak gain of -0.6%. It never reached the target. By the end of the window it was 52.96. The thesis missed.

What happened during the window

On September 10, 2025, Novo Nordisk announced plans to cut 9,000 jobs and lowered its 2025 profit forecast. On October 9, 2025, Novo Nordisk said it would acquire Akero Therapeutics for up to $5.2 billion.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals